BofA analyst Tazeen Ahmad raised the firm’s price target on Pharvaris to $11 from $8 and keeps an Underperform rating on the shares after the company announced the Phase 2 CHAPTER-1 trial evaluating deucrictibant as a prophylactic treatment for HAE achieved its primary endpoint. While “encouraged” by the positive data, which “provides some validation for deucrictibant’s clinical activity as a prophylactic treatment,” the firm continues to look for color on some key aspects and highlights that the prophylactic HAE program remains on clinical hold in the U.S.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PHVS:
- Pharvaris 11.125M share Secondary priced at $24.00
- Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
- Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Pharvaris announces ‘positive’ data from CHAPTER-1 study of deucrictibant
- Pharvaris to Present at the GA²LEN UCARE Conference 2023
Questions or Comments about the article? Write to editor@tipranks.com